Elizabeth Budde, MD, PhD

Articles by Elizabeth Budde, MD, PhD

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

ByElizabeth Budde, MD, PhD

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

December 19th 2023

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

ByDavid L. Porter, MD, University of Pennsylvania,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Elizabeth Budde, MD, PhD

October 16th 2020

Elizabeth Budde, MD, PhD

Articles by Elizabeth Budde, MD, PhD

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies